Search results
Results From The WOW.Com Content Network
AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA [3]) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with K i values of 10.04 nM at CB 1 and 0.786 nM at CB 2 and EC 50 values of 0.5433 nM at CB 1 and 0.1278 nM at CB 2, [4] and has been sold online as a designer drug.
Bag and contents of a well-known early brand of synthetic cannabinoids named Spice that contains herbs covered with synthetic cannabinoids, now illegal throughout much of the world. Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids (THC, CBD and many others) in cannabis plants ...
5F-CUMYL-PINACA (also known as SGT-25 and sometimes sold in e-cigarette form as C-Liquid) [1] is an indazole-3-carboxamide based synthetic cannabinoid. [2] 5F-CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with the original patent claiming approximately 4x selectivity for CB 1, having an EC 50 of <0.1 nM for human CB 1 receptors and 0.37 nM for human CB 2 receptors. [3]
FUB-APINACA (also known as A-FUBINACA according to the EMCCDA framework for naming synthetic cannabinoids [1] and FUB-AKB48) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB 1 receptor and has been sold online as a designer drug. [2]
CUMYL-4CN-BINACA (also known as CUMYL-CYBINACA or SGT-78) is an indazole-3-carboxamide based synthetic cannabinoid that has been sold online as a designer drug. [3 ...
ADB-CHMINACA (also known as ADMB-CHMINACA [3] and MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB 1 receptor with a binding affinity of K i = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. [4] [5] It was identified in cannabinoid blends in Japan in early 2015. [6]
ADB-BINACA (also known as ADMB-BZINACA using EMCDDA naming standards [1]) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products. [2] It was originally developed by Pfizer as a potential analgesic, and is a potent agonist of the CB 1 receptor with a binding affinity (K i) of 0.33 nM and an EC 50 ...
JWH-073, a synthetic cannabinoid, is an analgesic chemical from the naphthoylindole family that acts as a full agonist [3] at both the CB 1 and CB 2 cannabinoid receptors. It is somewhat selective for the CB 1 subtype, with affinity at this subtype approximately 5× the affinity at CB 2. [4]